Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells $115,663.68 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 792 shares of Natera stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $115,663.68. Following the completion of the sale, the chief financial officer now owns 71,869 shares of the company’s stock, valued at approximately $10,495,748.76. The trade was a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $151.15 on Friday. The company has a market capitalization of $20.43 billion, a P/E ratio of -85.88 and a beta of 1.80. The company’s 50-day moving average is $161.23 and its 200 day moving average is $149.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. On average, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

A number of large investors have recently bought and sold shares of the company. 111 Capital bought a new position in Natera during the fourth quarter worth about $397,000. Wealth Enhancement Advisory Services LLC boosted its holdings in Natera by 79.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,493 shares of the medical research company’s stock worth $3,086,000 after buying an additional 8,635 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Natera in the 4th quarter valued at approximately $19,210,000. HWG Holdings LP raised its holdings in Natera by 173.0% during the 4th quarter. HWG Holdings LP now owns 40,739 shares of the medical research company’s stock valued at $6,449,000 after acquiring an additional 25,819 shares during the period. Finally, Polar Asset Management Partners Inc. lifted its position in shares of Natera by 1.6% during the fourth quarter. Polar Asset Management Partners Inc. now owns 96,105 shares of the medical research company’s stock worth $15,213,000 after acquiring an additional 1,500 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday. Piper Sandler raised their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Barclays began coverage on shares of Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Finally, Morgan Stanley increased their price objective on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.